Flash Finance

Medicamen Biotech LimitedMEDICAMEQCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹284.45
MCap ₹386 Cr · P/E 1.4
Medicamen Biotech Limited — Stock analysis & AI research Medicamen Biotech Limited — Seasonality — best & worst months Medicamen Biotech Limited — Technical setup — score, trend, support & resistance Medicamen Biotech Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹44 Cr
Sales · Jun 2026
+14.1% YoY
₹5 Cr
Operating Profit · Jun 2026
+18.6% YoY
10.9%
OPM % · Jun 2026
+3.8% YoY
₹3 Cr
Net Profit · Jun 2026
+54.1% YoY
—
EPS · Jun 2026

📝 Medicamen Biotech Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Medicamen Biotech Limited reported revenue of ₹44 crore for the quarter ended June 2026 (Q1 FY27), up 14.1% from ₹38 crore in the same quarter last year, and down 19.8% sequentially over the March 2026 quarter.

Net profit rose 54.1% year-on-year to ₹3 crore, from ₹2 crore.

Operating profit stood at ₹5 crore — an operating margin (OPM) of 10.9%, compared with 10.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Medicamen Biotech Limited posted revenue of ₹4,484 crore, a growth of 1519.4% over FY25, with a net profit of ₹266 crore (down 43.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹4,490 crore with a net profit of ₹267 crore.

Valuation snapshot

At the current price of ₹284.45, MEDICAMEQ has a market capitalisation of ₹386 crore and a trailing P/E of about 1.4.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 14th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 40.46%, foreign institutional investors (FIIs) 0.10%, domestic institutional investors (DIIs) 0.00%, the government 0.05%, public shareholders 59.39% of Medicamen Biotech Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹386 Cr
Current Price ?
₹284.4
P/E ?
1.44below ind
Industry P/E ?
21.30
P/B ?
1.38
P/S ?
0.09
P/FCF ?
-11.35
Enterprise Value ?
₹423 Cr
EV/EBITDA ?
0.81
PEG ?
N/A
Earnings Yield ?
80.8%
Dividend Yield ?
0.33%
Profitability & Returns
Sales (TTM) ?
₹4,490 Cr
OPM ?
11.6%
Profit after tax (TTM) ?
₹267 Cr
EPS (TTM) ?
₹196.97
ROCE ?
5.0%
ROE ?
95.4%
ROA ?
73.8%
Growth
Sales — latest qtr ?
₹44 Cr
PAT — latest qtr ?
₹3 Cr
YoY qtr sales growth ?
14.1%
YoY qtr profit growth ?
54.1%
Sales growth (3y) ?
9%
Sales growth (5y) ?
10%
Profit growth (3y) ?
-14%
Profit growth (5y) ?
-6%
Financial Health
Debt ?
₹37 Cr
Debt to Equity ?
0.13
Interest Coverage ?
4.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
40.46%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
19.2%
Return 6 months ?
10.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 374143444541434115138424,3495544 +14.1% -19.8%
Operating Profit 7766751,1416174550845 +18.6% +16.0%
Other Income 0011118606005321 +83.3% -50.2%
Interest 11112116913117811 +14.2% +6.6%
Depreciation 222222431272217522 -1.5% +0.8%
Profit Before Tax 5544436273132330843 +50.1% -7.4%
Net Profit 443332453392225933 +54.1% -14.9%
EPS 3.203.492.382.192.441.781.791.987.431.211.631.912.19— — —
OPM % 18.2% 18.3% 14.4% 12.6% 15.2% 11.7% 2663.2% 15.2% 10.9% 10.5% 12.0% 11.7% 7.5% 10.9% +3.8% +45.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹277 Cr ₹4,484 Cr ₹4,490 Cr +1519.4%
Operating Profit ₹1,169 Cr ₹521 Cr ₹522 Cr -55.4%
OPM % 421.98% 11.62% 11.62% -97.2%
NPM % 168.60% 5.94% 5.95% -96.5%
Other Income ₹93 Cr ₹56 Cr ₹56 Cr -40.0%
Depreciation ₹442 Cr ₹180 Cr ₹180 Cr -59.2%
Interest ₹173 Cr ₹80 Cr ₹80 Cr -53.8%
EBIT ₹726 Cr ₹341 Cr ₹342 Cr -53.1%
PBT ₹646 Cr ₹317 Cr ₹318 Cr -51.0%
Tax ₹179 Cr ₹49 Cr ₹50 Cr -72.4%
Net Profit ₹467 Cr ₹266 Cr ₹267 Cr -43.0%
EPS ₹12.98 ₹6.94 ₹5.73 -46.5%
Material Cost ₹117 Cr ₹2,146 Cr ₹2,168 Cr +1738.8%
Employee Cost ₹27 Cr ₹559 Cr ₹565 Cr +1968.1%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CWIP 0000 —
Equity Capital 13131314 +7.7%
Reserves 181196205266 +29.8%
Borrowings 26302737 +37.0%
Other Liabilities 57554845 -6.2%
Total Liabilities 277294293362 +23.5%
Fixed Assets 92918684 -2.3%
Investments 4888 +0.0%
Other Assets 180195199270 +35.7%
Total Assets 277294293362 +23.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity -4-0-3-29 -866.7%
Cash from Investing Activity -8-9-2-3 -50.0%
Cash from Financing Activity 283-760 +957.1%
Net Cash Flow 17-6-1128 +354.5%
Free Cash Flow -10-6-5-34 -580.0%
CFO/OP -27%10%-7%-149% -2028.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 159102141132 -6.4%
Inventory Days 230237274258 -5.8%
Days Payable 232152182138 -24.2%
Cash Conversion Cycle 157188234252 +7.7%
Working Capital Days 151117186197 +5.9%
ROCE % 11%10%7%5% -28.6%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 40.46%40.46%40.46%40.46% +0.0%
FIIs 0.00%0.05%0.02%0.10% +400.0%
DIIs 0.64%0.59%0.44%0.00% -100.0%
Government 0.05%0.05%0.05%0.05% +0.0%
Public 58.83%58.84%59.02%59.39% +0.6%
No. of Shareholders 10,80811,17710,96710,806 -1.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Medicamen Biotech Limited's revenue in Q1 FY27?
Medicamen Biotech Limited reported revenue of ₹44 crore for the quarter ended June 2026 (Q1 FY27), up 14.1% from ₹38 crore in the same quarter last year, and down 19.8% sequentially over the March 2026 quarter.
What was Medicamen Biotech Limited's net profit in Q1 FY27?
Net profit rose 54.1% year-on-year to ₹3 crore, from ₹2 crore.
What is MEDICAMEQ's market capitalisation and P/E ratio?
At the current price of ₹284.45, MEDICAMEQ has a market capitalisation of ₹386 crore and a trailing P/E of about 1.4.
Who owns Medicamen Biotech Limited? (shareholding pattern)
As of Mar 2026, promoters held 40.46%, foreign institutional investors (FIIs) 0.10%, domestic institutional investors (DIIs) 0.00%, the government 0.05%, public shareholders 59.39% of Medicamen Biotech Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI